N-of-One To Collaborate With OncoDNA to Provide Personalized Cancer Therapy

A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.

N-of-One, Inc. , the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with OncoDNA, the first company in Europe to provide personalized medicine in oncology based on the molecular analysis of each patient’s tumor. Under this agreement, N-of-One will provide the clinical interpretation for all of OncoDNA’s next-generation sequencing (NGS) and other molecular tests done for patients throughout Europe, the Middle East, and in other parts of the world. Financial terms of the agreement are not disclosed.

OncoDNA provides comprehensive tumor profiling services in order to assist medical doctors in their treatment choices and provide better monitoring of the evolution of patient tumors. The lab is led by a team of highly experienced experts in DNA sequencing and diagnostic analyses in oncology.

N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge and insights related to the mutation profile of a tumor identified by sequencing linking this knowledge to relevant therapeutic strategies, including clinical trials.

Read the press release here: http://on.mktw.net/1lIkNTh

Source: MarketWatch